Audentes Therapeutics closes $30 million Series A financing

Audentes Therapeutics, Inc., a recently founded biotechnology company dedicated to the development of innovative treatments for rare muscle diseases, today announced the closing of a $30 million Series A financing. The financing was led by OrbiMed Advisors with the participation of 5AM Ventures and Versant Ventures. This funding will allow the Company to further advance its two lead programs, AT001 for X-linked Myotubular Myopathy (XLMTM) and AT002 for Pompe disease, and to evaluate additional candidate programs. Both AT001 and AT002 are innovative, novel treatments based on adeno-associated virus (AAV) gene therapy technology.

“Our focused, experienced team is committed to advancing the promising scientific approach of gene therapy and looks forward to collaborating closely with our patient, research and medical community partners in this process.”

"This financing is a tremendous step forward for the development of new potential treatments for patients affected by very serious orphan muscle diseases. I'm delighted to have the opportunity to work with such a fantastic group of people who share our vision for success in bringing these therapies to patients," said Matthew R. Patterson, President and Chief Executive Officer of Audentes. "Our focused, experienced team is committed to advancing the promising scientific approach of gene therapy and looks forward to collaborating closely with our patient, research and medical community partners in this process."

Source:

Audentes Therapeutics, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Canadian Coalition Fosters Collaboration in Fight Against COVID-19